Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

of LX1031 has progressed with the goal of achieving a lower and less frequent dosing regimen that will provide a similar safety and efficacy profile to that observed with the original formulation.  In addition, LX1033, a back-up compound that is approximately 10-fold more potent than LX1031, has completed IND-enabling studies.  It is anticipated that LX1033 will commence Phase 1 testing in the first quarter of 2011.
  • Rheumatoid Arthritis:  Lexicon completed dosing in the expanded Phase 2a clinical trial of its drug candidate for rheumatoid arthritis, LX2931, an inhibitor of sphingosine-1-phosphate lyase.  Top-line data from the study, which enrolled 208 patients and was conducted at multiple centers in the United States and Eastern Europe, are expected to be available by the end of the year.
  • Carcinoid Syndrome:  Enrollment in both the United States and Europe is continuing in the Phase 2a trials for LX1032, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels. Preliminary data from both trials are expected to be available in the first half of 2011.

  • Financial Results and EventsOn July 30, 2010, Lexicon exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.  Pursuant to the amended terms of the purchase option, Lexicon paid Symphony Icon Holdings LLC $10 million and agr
    '/>"/>

    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
    2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
    3. Lexicon to Present at Two Major Healthcare Investor Conferences
    4. Lexicon Announces Pricing of Common Stock in Public Offering
    5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
    6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
    7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
    9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
    10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
    11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... 25, 2014 Research and Markets ... Metabolomics Market 2014-2018" report to their offering. ... Metabolomics or Metabonomics is the scientific study ... a new experimental technique that is being widely ... Metabolites are small molecules that are present in ...
    (Date:7/25/2014)... California (PRWEB) July 25, 2014 Lawrence ... named to Thomson Reuters list of " The World's ... are part of the 3,000 researchers who were identified ... to recognize those who published the highest-impact work (2002-2012 ... research papers on combustion modeling . , "This ...
    (Date:7/25/2014)... BEIJING , July 25, 2014 Sinovac Biotech ... biopharmaceutical products in China , today announced ... second quarter ended June 30, 2014, after market close on ... conference call prior to the market opening on Friday, August ... at 8:00 p.m. China Standard Time) to review the Company,s ...
    (Date:7/24/2014)... July 24, 2014  Now available is a stem ... Rehealth Regenerative Therapies , located in Guadalajara, ... active people a new health option: stem cell ... age, countless patients suffer from joint and muscle injuries ... muscle tears, torn rotator cuff, tennis elbow, and knee ...
    Breaking Biology Technology:Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
    ... at American Society of Pharmacognosy, EMERYVILLE, Calif., ... will present seminal information on a new drug ... 7th Annual Oxford International,Conference on the Science of ... April 12-16, 2008. Scott Baggett, Ph.D., a member ...
    ... April 14 Codexis, Inc. announced,today that it has ... U.S.,Securities and Exchange Commission ("SEC") relating to the proposed ... of the Codexis,registration statement on Form S-1 can be ... shares being offered and the price,range for the offering ...
    ... and reduced cost for ... pharmaceutical manufacturers, NEW YORK, ... agreement with Chiral Quest, Inc., a manufacturer and,developer of chiral ... chiral products to the pharmaceutical industry., Effective immediately, Sumitomo ...
    Cached Biology Technology:Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness 2Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness 3Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering 2Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest 2
    (Date:7/24/2014)... use of native animal species for food or commercial ... significant factor in the decline of many species of ... indicates that more than half of the species being ... hornbills., "By surveying not only the meat made available ... inside the forest by hunters and brought to villages ...
    (Date:7/24/2014)... has identified two factors that characterize sustainable university ... of highly qualified physics teachers. Specifically, one or ... teacher education in combination with institutional motivation and ... Science, Technology, Engineering and Math (STEM) teacher shortages ... points the way for institutions seeking to increase ...
    (Date:7/24/2014)... Some sticky research out of York University shows ... species of toxic grass fungus: moose saliva (yes moose ... Letters , "Ungulate saliva inhibits a grassendophyte mutualism" shows ... fescue grass (which hosts a fungus called epichlo festucae ... growth and less toxicity. , "Plants have evolved defense ...
    Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2
    ... known for years that damaged DNA can lead to human ... it--has remained less clear. , Now, computational chemists at ... that when a proton is knocked off one of the ... damage begins that causes "lesions" in the DNA. These lesions, ...
    ... the IODP Arctic Coring Expedition (ACEX) is making news with ... of Nature, an article by several of the expedition scientists ... warm, unusually wet, and ice-free up to the time the ... Earth's atmosphere ?a period calculated to have occurred 55 million ...
    ... the more advanced species stopped making a protein that ... the HIV-1 virus from entering and infecting blood cells. ... designed to prevent infections. But a research team led ... of Biomedical Sciences has demonstrated that over 100 days ...
    Cached Biology News:'Pinball protons' created by ultraviolet rays and other causes can lead to DNA damage 2Arctic coring expedition continues to yield new clues 2Defense peptide found in primates may block some human HIV transmissions 2Defense peptide found in primates may block some human HIV transmissions 3